The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases

ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTThe Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic DiseasesAhmed F. Abdel-Magid*Ahmed F. Abdel-MagidTherachem Research Medilab, LLC, 100 Jade Park, Chelsea, Alabama 35043, United States*Email: [email protected]More by Ahmed F. Abdel-Magidhttps://orcid.org/0000-0001-7438-1414Cite this: ACS Med. Chem. Lett. 2022, 13, 1, 19–21Publication Date (Web):December 27, 2021Publication History Received8 December 2021Published online27 December 2021Published inissue 13 January 2022https://doi.org/10.1021/acsmedchemlett.1c00678Copyright © Published 2021 by American Chemical SocietyRIGHTS & PERMISSIONSArticle Views2319Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (858 KB) Get e-Alerts Get e-Alerts